Navigation Links
Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference
Date:12/4/2008

PLYMOUTH MEETING, Pa., Dec. 4 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced that Jack Armstrong, President and CEO of Genaera, is scheduled to present at the 2008 RBC Capital Markets Healthcare Conference. The presentation is part of an RBC Capital Markets' panel discussion of obesity, entitled, "Shrinking The Obesity Epidemic," and will take place at the Westin Times Square Hotel in New York on Wednesday, December 11 at 11:00 a.m. ET.

This panel presentation is being webcast at: www.wsw.com/webcast/rbc95/panel6

About Genaera

Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma. For further information, please see our website at www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to the risks and uncertainties discussed in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.


'/>"/>
SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Genaera to Present at Therapeutic Area Partnerships 2008
2. Genaera Receives Non-Compliance Notice From NASDAQ
3. Genaera Corporations 2008 Annual Stockholder Meeting Results
4. Xmark Comments on Genaera Cost-Saving Plan
5. Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
6. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
7. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
8. ATS Medical to Participate at the RBC Capital Markets Healthcare Conference
9. Individuals Associated with Vinson Hall Retirement Community, Who Survived Pearl Harbor Attack, to Participate in Navy Memorial Event December 7
10. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
11. DURECT Corporation to Participate in Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a ... the finalization of the company’s executive management team with prominent executives from both inside ... Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more than twenty ...
(Date:3/29/2017)... ... March 29, 2017 , ... Hamlin Dental Group, multi-location dental office in ... treatments. Dental lasers are safe and effective options, and can be used alone or ... the overall quality of care. , Dr. Hamid Reza of Hamlin Dental Group offers ...
(Date:3/29/2017)... ... ... has helped over 1.5 million SharePoint users learn the content management system faster and ... for SharePoint was at the farm level. Enterprises using SharePoint Online in Office 365 ... recently released a modified version of the Help System, VisualSP for Site Collections, which ...
(Date:3/28/2017)... ... March 28, 2017 , ... Greenfield Advisors is ... his extensive knowledge of appraisals, property values, ad valorem taxation, and government policy ... industry for more than 40 years. , “Ruel is a great addition to ...
(Date:3/28/2017)... ... 28, 2017 , ... City trips have soared 82% since ... Report). As travelers visit both urban destinations, they are faced with exploration that ... In response, the outdoor industry has blurred the lines between fashion and function ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... -- The Pharmaceutical Care Management Association (PCMA) today released the ... out-of-pocket spending: According to ... average amount spent out-of-pocket for drugs continues to decline, ... down from 23% in 2006. Rising ... problem. Health plans don,t have unlimited funds to pay ...
(Date:3/29/2017)... 2017 Research and Markets has announced the ... 2023" report to their offering. ... The ablation device global market is expected ... by 2023. Ablation is the minimally invasive therapeutic ... cancerous or diseased tissue removal, to the removal of abnormally conducting ...
(Date:3/29/2017)... 29, 2017  Spiral Therapeutics, Inc. today announced ... Farma, S.L. for the worldwide exclusive rights to ... the field of otolaryngology for aggregate payments of ... The agreement provides Spiral with the option to ... product profile. Under the terms of the agreement, ...
Breaking Medicine Technology: